In This SectionTexas Health Research & Education Institute
Disease or Condition
Bacterial Infection / Pneumonia
A Multicenter, Retrospective Cohort Study to Characterize the Use of Teflaro® in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection or Community-acquired Bacterial Pneumonia
This is a multicenter, retrospective cohort study of adult patients treated with IV Teflaro
for acute bacterial skin and skin structure infection (ABSSSI) or community-acquired bacterial pneumonia (CABP) between 01 Jan 2011 and the end of the data collection period.
Male or female = 18 years of age at the time of receipt of Teflaro.
Diagnosed with ABSSSI or CABP, generally defined as:
ABSSSI: A skin or skin structure infection involving deeper soft tissue or requiring significant surgical intervention, such as a wound infection (surgical or traumatic), a major abscess, an infected ulcer, or deep and extensive cellulitis OR ?
CABP: An acute illness with clinical signs or symptoms consistent with a lower respiratory tract infection and radiographically confirmed pneumonia (new or progressive pulmonary infiltrate[s] on chest radiograph consistent with bacterial pneumonia).
Received = 2 consecutive IV doses of commercial Teflaro per the institution’s standard of care between 01 Jan 2011 and the end of the data collection period.
Received the final dose of Teflaro = 30 days before the start of data collection.
Hospital discharge information (eg, date and destination of discharge) is missing from the patient’s chart.
Teflaro dosing information (eg, start and stop information) is missing from the patient’s chart.
The patient received > 1 treatment cycle with Teflaro, and data for 1 cycle from the patient’s chart has been extracted for this study.